Impacts of the COVID‐19 pandemic on early detection of prostate cancer in Australia

Ip, Christopher Chi Kit; Kealey, Joshua; Davis, Ian D.; Sengupta, Shamik

doi:10.1111/bju.15631

Cited by 5 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven studies [ 31 , 32 , 36 , 39 , 58 , 65 , 74 ] scored 1 point because of statistical differences in the most or second-most important factors. Forty-five studies [ [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , 33 , 34 , 37 , 38 , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [53] , [54] , [55] , [56] , [57] , [59] , [60] , [61] , [62] , [63] , [64] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , 75 , 76 ] scored 0 point in view of the lack of control over the most or second-most important factors in the comparability domain.…”

Section: Resultsmentioning

confidence: 99%

Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review

Wang,

Yang,

Xiong

et al. 2024

Fundamental Research

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review

Wang,

Yang,

Xiong

et al. 2024

Fundamental Research

View full text Add to dashboard Cite

“…The confirmatory prostate biopsy will be transperineal and will be performed by the treating urologist 3–9 months after the initial diagnostic biopsy, and shortly after the repeat mpMRI and the pelvic PSMA PET/CT scan. A range for biopsy timeframe has been given due to COVID‐19 restrictions and access to hospitals [21,22]. There will be three different ‘types’ of biopsy performed at the confirmatory biopsy (Table 2): Systematic biopsy of the prostate The template for biopsy requires systematic sampling of the prostate with a minimum of 18 cores, dependent on prostate volume [23].…”

Section: Design and Methods: Confirm Trial Protocolmentioning

confidence: 99%

“…The confirmatory prostate biopsy will be transperineal and will be performed by the treating urologist 3-9 months after the initial diagnostic biopsy, and shortly after the repeat mpMRI and the pelvic PSMA PET/CT scan. A range for biopsy timeframe has been given due to COVID-19 restrictions and access to hospitals [21,22]. There will be three different 'types' of biopsy performed at the confirmatory biopsy ( a. Intraprostatic lesions with scores ≥3 of either E-PSMA 'reader confidence' or PRIMARY will be targeted at confirmatory biopsy (Table 3), as will lesions with a maximum standardised uptake value (SUV max ) of ≥2.5 or a tumour:background ratio ≥1.5.…”

Section: Prostate Biopsymentioning

confidence: 99%

The CONFIRM trial protocol: the utility of prostate‐specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer

Bagguley,

Harewood,

McKenzie

et al. 2023

BJU International

View full text Add to dashboard Cite

ObjectivesPrimary objectives: To determine the additive value of prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the risk stratification of men with newly diagnosed prostate cancer (PCa) who would have otherwise been deemed suitable for active surveillance (AS). Specifically, we aim to determine if PSMA PET/CT can detect a cohort of men on AS that are in fact high risk and likely to experience unfavourable outcomes should they remain on their current treatment pathway. Secondary objectives: to determine the additive value of PSMA PET/CT to repeat multiparametric magnetic resonance imaging (mpMRI) of the prostate and explore whether a confirmatory biopsy may be avoided in men with a negative PSMA PET/CT and a negative repeat mpMRI of the prostate (Prostate Imaging‐Reporting and Data System score of <3). Furthermore, to develop a nomogram combining clinical, imaging and biomarker data to predict the likelihood of failure on AS in men with high‐risk features. Also, a blood sample will be taken to perform a Prostate Health Index test at the time of confirmatory biopsy. Furthermore, a portion of this blood will be stored at a biobank for up to 5 years if a follow‐up study on molecular biomarkers and genetic assays in this cohort of men is indicated, based on the results from the CONFIRM trial.Patients and MethodsThe CONFIRM trial is a prospective, multicentre, pre‐test/post‐test, cohort study across Victoria, Australia, involving men with newly diagnosed low‐risk PCa with high‐risk features, considered suitable for AS and undergoing confirmatory biopsy. The trial's goal is to provide high‐quality evidence to establish whether PSMA PET/CT has a role in risk‐stratifying men deemed suitable for AS despite having high‐risk feature(s).ResultsThe CONFIRM trial will measure the proportion of men deemed unsuitable for ongoing AS based on pathological upgrading and multidisciplinary team recommendation due to PSMA PET/CT scan and PSMA‐targeted confirmatory biopsy. Additionally, the positive and negative predictive values, sensitivity, and specificity of PSMA PET/CT will be calculated in isolation and combined with repeat mpMRI of the prostate.ConclusionsThis trial will provide robust prospective data to determine if PSMA‐PET/CT and standard of care (prostate biopsy ± repeat mpMRI) can improve diagnostic certainty in men undergoing confirmatory biopsy for low‐grade PCa with high‐risk features.

show abstract

“…23 31 Another one was performed in the USA, where the average monthly number of prostate biopsy results decreased by 37.9% during the early stage of the pandemic and rebounded to 18.1% during the late stage of the pandemic. 30…”

Section: Biopsymentioning

confidence: 99%

COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review

Mostafavi Zadeh,

Tajik,

Gheytanchi

et al. 2023

BMJ Support Palliat Care

View full text Add to dashboard Cite

IntroductionThe healthcare level has been greatly affected by the COVID-19 pandemic compared with before the outbreak. This study aimed to review the impact of COVID-19 on the screening and diagnosis of prostate cancer (PCa).MethodThe current study was designed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020. The keywords used to perform the search strategy were COVID-19 and prostate neoplasms. The four primary electronic databases comprising PubMed/MEDLINE, Web of Science, Scopus and Embase were searched until 1 September 2022. After screening and selecting studies through the EndNote software, data were extracted from each included study by two independent authors. All studies were evaluated according to Newcastle–Ottawa Scale quality assessment tool.ResultsAs a result, 40 studies were included, categorised into two subjects. The majority of studies indicated a significant decrease in screening prostate-specific antibody tests during the COVID-19 pandemic compared with the pre-pandemic period, leading to delays in cancer diagnosis. The decrease in the number of diagnosed cases with low/intermediate stages to some extent was more than those with advanced stages. The PCa screening and diagnosis reduction ranged from nearly 0% to 78% and from 4.1% to 71.7%, respectively.ConclusionOur findings showed that during the COVID-19 lockdown, delays in PCa screening tests and diagnoses led to the negative health effects on patients with PCa. Thus, it is highly recommended performing regular cancer screening to reduce the impact of the COVID-19 lockdown.PROSPERO registration numberCRD42021291656.

show abstract

Impacts of the COVID‐19 pandemic on early detection of prostate cancer in Australia

Cited by 5 publications

References 6 publications

Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review

Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review

The CONFIRM trial protocol: the utility of prostate‐specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer

COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review

Contact Info

Product

Resources

About